ERBB2 and breast carcinoma: This finding would lead us to the idea that this new HER2-low group could be a distinct biological subtype with unique clinicopathological traits and needs to come into consideration as an additional subtype to the classical classification of the HER2-positive vs. negative and would expand the traditional subgroups of HER2 expression in breast cancer patients.